ARMONK, N.Y. and CAMARILLO, Calif., April 15 /PRNewswire/ -- IBM (NYSE: IBM) and California contract manufacturer Golden State Medical Supply (GSMS) today announced GSMS will be ready to comply with California's landmark prescription drug pedigree regulations this year. GSMS is using IBM technology to manage serialized drug pedigree information and offer new services to their customers.
The California Board of Pharmacy recently gave the pharmaceutical industry a two-year extension to January 1, 2011 to comply with its regulations, which are the first of their kind. The GSMS-IBM collaboration will be ready to begin this summer, well in advance of the state's original effective date.
The issue of the safety of the world's prescription drug supply is continuing to gain attention. The Center for Medicines in the Public Interest projects that global revenues lost due to counterfeit drug sales will reach $75 billion by 2010, a 92 percent increase from 2005.
"We applaud the efforts of any company that continues to work toward meeting the original 2009 deadline for compliance with California's electronic pedigree system," said Virginia Herold, executive director of the California State Board of Pharmacy. "We believe the California law for electronic pedigree is the most effective means to add security to the pharmaceutical supply chain."
In addition to enabling GSMS to act in accordance with new and emerging ePedigree regulations, IBM's Solution for Pharmaceutical Track & Trace will give GSMS the technology infrastructure to offer new services for the pharmaceutical industry. For example, the company could provide ePedigree compliance services to manufacturers that have not yet determined how they will comply with the California regulations.
"We chose to team with IBM because GSMS is committed to protecting the
pharmaceutical drug supply. The issue of counterfeit drug sales is an
important one for our industry and our work with IBM
|SOURCE Golden State Medical Supply, Inc.|
Copyright©2008 PR Newswire.
All rights reserved